Purpose: To retrospectively assess the efficacy and safety of FemoSeal® vascular closure device to achieve hemostasis following antegrade common femoral artery puncture after lower limb revascularization using vascular sheaths from 5 to 8 Fr. Methods: We reviewed the hemostatic outcome achieved with FemoSeal in 103 consecutive patients (mean age: 69 ± 8 years, 71 males) that undergone to 111 antegrade common femoral artery accesses for percutaneous lower limbs revascularization using 5- to 8-Fr vascular sheaths. We used FemoSeal in an unselected population, without exclusion criteria. The primary outcome was the technical success, meant as achieving complete hemostasis without immediate complications. Results: Hemostasis was achieved in all...
ObjectiveTo retrospectively evaluate the efficacy and time-to-hemostasis of antegrade femoral access...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
A new device (prostarTm, Perclose, Inc.) was developed to close femoral artery access sites percutan...
Objective: The purpose of this study was to evaluate the safety and efficacy of a hemostatic punctur...
8PURPOSE: To report a retrospective evaluation of the 6-F Angio-Seal closure device in antegrade a...
OBJECTIVE: The aim of this review was to provide an up-to-date summarization of available Food and D...
Purpose: To assess the technical success and complications of Angio-Seal vascular closure device in ...
Background: We evaluated the long term clinical outcomes of femoral vascular closure devices followi...
ObjectivesSmall published series suggest a higher failure rate for Angio-Seal vascular closure devic...
Purpose: To assess the safety and efficacy of the StarClose device following peripheral vascular int...
Antegrade femoral artery access is commonly used for percutaneous transluminal revascularization of ...
AbstractBackgroundAs vascular surgeons perform increasing numbers of percutaneous catheter–based pro...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
ObjectiveTo retrospectively evaluate the efficacy and time-to-hemostasis of antegrade femoral access...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
A new device (prostarTm, Perclose, Inc.) was developed to close femoral artery access sites percutan...
Objective: The purpose of this study was to evaluate the safety and efficacy of a hemostatic punctur...
8PURPOSE: To report a retrospective evaluation of the 6-F Angio-Seal closure device in antegrade a...
OBJECTIVE: The aim of this review was to provide an up-to-date summarization of available Food and D...
Purpose: To assess the technical success and complications of Angio-Seal vascular closure device in ...
Background: We evaluated the long term clinical outcomes of femoral vascular closure devices followi...
ObjectivesSmall published series suggest a higher failure rate for Angio-Seal vascular closure devic...
Purpose: To assess the safety and efficacy of the StarClose device following peripheral vascular int...
Antegrade femoral artery access is commonly used for percutaneous transluminal revascularization of ...
AbstractBackgroundAs vascular surgeons perform increasing numbers of percutaneous catheter–based pro...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
ObjectiveTo retrospectively evaluate the efficacy and time-to-hemostasis of antegrade femoral access...
BACKGROUND: Given the frequent involvement of infra-popliteal arteries, an ipsilateral antegrade com...
A new device (prostarTm, Perclose, Inc.) was developed to close femoral artery access sites percutan...